Skip to main content
Product > ViruBot™ TPC1, TPC2, and TPC3

ViruBot™ TPC1, TPC2, and TPC3

ViruBots™ are engineered viruses.  These extremely small “bots” target cancer cells in unique ways.  They also stimulate the immune system to act against cancer cells.  Timothy P. Cripe, MD, PhD, of Nationwide Children’s Hospital and The Ohio State University has provided a suite of immunotherapy technologies to Open Therapeutics for global crowd-sourcing.  This suite of ViruBots have peer review published in vivo results.  Assisted by Drs. Su, Guo, Samy, Krishnamoorthy, Dr. Cripe is developing these ViruBots to target fourteen different cancer types as well as neoplasm.

Want to save these project details? Download this brief Project Manifest for your convenience!

We Believe

How open science helps researchers succeed

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers. We review literature demonstrating that open research is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open research practices bring significant benefits to researchers relative to more traditional closed practices.